SIAG
BBC icon

Safeguard Investment Advisory Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Safeguard Investment Advisory Group’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed – – 130
2020
Q4 		$0 Buy
+20
New +$898 ﹤0.01% 714

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Safeguard Investment Advisory Group's BBC Position: Q1 2021 in Review

Safeguard Investment Advisory Group sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2021, closing a stake of 20 shares.

Safeguard Investment Advisory Group first reported a position in BBC in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 22 funds tracked by Wall St. Rank hold BBC as of Q1 2021.

  • Safeguard Investment Advisory Group reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2021 after selling out during the quarter.
  • Safeguard Investment Advisory Group sold 20 Virtus Biotech Clinical Trials ETF shares in Q1 2021.
  • Safeguard Investment Advisory Group first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2020 and held it in 1 quarter.
  • Safeguard Investment Advisory Group's Virtus Biotech Clinical Trials ETF position peaked at $0 in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2021.

Based on Safeguard Investment Advisory Group's 13F filing for Q1 2021, filed 10 May 2021.